Compass Capital Corp MA ADV Reduces Position in Johnson & Johnson (NYSE:JNJ)

Compass Capital Corp MA ADV lowered its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 51.7% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,754 shares of the company's stock after selling 1,879 shares during the period. Compass Capital Corp MA ADV's holdings in Johnson & Johnson were worth $274,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. grew its position in Johnson & Johnson by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 232,792,559 shares of the company's stock worth $33,666,460,000 after purchasing an additional 1,772,706 shares during the last quarter. Geode Capital Management LLC grew its position in Johnson & Johnson by 2.8% during the 4th quarter. Geode Capital Management LLC now owns 57,667,920 shares of the company's stock worth $8,321,881,000 after purchasing an additional 1,561,036 shares during the last quarter. Northern Trust Corp grew its position in Johnson & Johnson by 12.3% during the 4th quarter. Northern Trust Corp now owns 30,813,175 shares of the company's stock worth $4,456,201,000 after purchasing an additional 3,363,235 shares during the last quarter. Norges Bank purchased a new stake in Johnson & Johnson during the 4th quarter worth approximately $4,390,037,000. Finally, Wellington Management Group LLP grew its position in Johnson & Johnson by 1.8% during the 4th quarter. Wellington Management Group LLP now owns 24,356,572 shares of the company's stock worth $3,522,447,000 after purchasing an additional 431,205 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on JNJ. Leerink Partners downgraded shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and dropped their price objective for the company from $169.00 to $153.00 in a report on Tuesday, May 13th. Guggenheim reaffirmed a "neutral" rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $181.00 price objective on shares of Johnson & Johnson in a report on Thursday, June 5th. Leerink Partnrs downgraded shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Finally, Sanford C. Bernstein reaffirmed a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Eleven equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $170.88.

Johnson & Johnson Price Performance

NYSE:JNJ traded down $0.92 during trading hours on Friday, reaching $149.81. 22,591,152 shares of the company were exchanged, compared to its average volume of 8,022,556. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49. The stock's 50-day moving average is $154.07 and its 200-day moving average is $153.63. The firm has a market cap of $360.44 billion, a PE ratio of 16.66, a price-to-earnings-growth ratio of 2.28 and a beta of 0.42. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. The company had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were given a dividend of $1.30 per share. The ex-dividend date was Tuesday, May 27th. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a yield of 3.47%. Johnson & Johnson's dividend payout ratio is currently 57.84%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.